Key Highlights

  • Prescient Therapeutics Ltd (ASX:PTX) shares were priced at $0.061 during the 20 October 2026 session, a gain of 10.91%.
  • The PTX-100 Phase 2a study in cutaneous T-cell lymphoma reached 20 evaluable patients, 10 in each of two dosing arms, with the first Dose Optimisation Committee review due in December 2026.
  • The company reported cash of $5.8 million at 30 September 2026, or a pro forma $11.8 million including a $6.0 million Capital raise received on 1 October 2026.

During the Trading session on 20 October 2026, Prescient Therapeutics Ltd (ASX:PTX) shares were priced at $0.061, a gain of 10.91%. On 13 October 2026 the company released its September 2026 Activities Report and Appendix 4C Cash Flow Statement for the quarter ended 30 September 2026. The report covered enrolment progress in the PTX-100 Phase 2a study, the completion of a $6.0 million capital raise, a new Chief Medical Officer and the company's cash position at quarter end.

Company Background

Prescient Therapeutics is a Melbourne-based, clinical-stage oncology company developing personalised cancer treatments through targeted therapies and cell therapy enhancement platforms. Its lead asset, PTX-100, is described by the company as a first-in-class compound that blocks an enzyme known as geranylgeranyl transferase-1 (GGTase-1), disrupting oncogenic Ras pathways in cancer cells. The company notes that Ras pathway mutations are believed to be involved in up to 22 per cent of all cancers.

PTX-100 has completed a Phase 1b expansion cohort study in T-cell lymphomas. The US Food and Drug Administration (FDA) has granted it Orphan Drug Designation for all T-cell lymphomas and Fast Track Designation for adults with relapsed or refractory mycosis fungoides, the most common subtype of cutaneous T-cell lymphoma (CTCL). A Phase 2 study in relapsed or refractory CTCL is recruiting globally. Prescient also holds the OmniCAR universal immune receptor platform, which is in preclinical development, and the CellPryme-A and CellPryme-M technologies designed to enhance cellular immunotherapy.

PTX-100 Phase 2a Study Update

The company said the Phase 2a study reached its pre-specified enrolment threshold for the first planned Dose Optimisation Committee (DOC) review, as first announced on 2 September 2026. Ten evaluable patients are enrolled in each of the two dosing arms, giving 20 in total; patients are evaluable after four cycles of treatment.

Three patients were enrolled during the quarter, taking total enrolment to 29 patients at 30 September 2026, from 26 at 30 June 2026. Prescient attributed the pace to the Northern Hemisphere summer slowdown, as most sites are located there. The trial has sites in Australia, the United States and Italy, with work under way to open sites in France, and enrolment continues towards 40 evaluable patients. The company stressed that the December DOC review is a planned milestone and not the completion of the study.

Capital Raise, Cash Flow and Corporate Changes

Prescient completed a Share Purchase Plan raising $4.8 million after final reconciliation, followed by a Placement of about $1.2 million, for approximately $6.0 million before costs. Both were priced at $0.065 per share, shares were allotted on 30 September 2026 and funds were received on 1 October 2026.

The Appendix 4C shows cash of $5.786 million at 30 September 2026, down from $9.028 million at the start of the quarter. Net operating cash outflows were $3.215 million, including $1.973 million of Research and Development payments. Payments to related parties, being non-executive director fees, totalled $80,000. Interest received was $79,000 and staff costs were $658,000. Dr Rosalind Wilson commenced as Chief Medical Officer on 13 July 2026 and leads clinical development strategy, including the Phase 2 CTCL study.

Sector Backdrop

Prescient's cell therapy platforms sit within the CAR-T segment of oncology. In June 2025 the US FDA eliminated the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved autologous CAR-T therapies, a change reported by regulatory and industry publications at the time. Market research firms publish differing forecasts for the CAR-T market, which are projections rather than reported results.

Risks Shareholders Should Weigh

Prescient is a clinical-stage company and reported no receipts from customers in the quarter. Its Appendix 4C shows estimated funding of 1.80 quarters at 30 September 2026; the company states the pro forma figure including the $6.0 million raise is 3.67 quarters, and that it expects net operating cash outflows to remain broadly consistent with recent quarters. Companies at this stage typically depend on further funding or partnerships.

Clinical outcomes carry inherent uncertainty. The DOC will review safety and efficacy data and provide guidance, and the 40-patient enrolment target has not yet been reached. OmniCAR remains preclinical, and Business development discussions on its platforms may or may not lead to agreements. Enrolment depends on site activity, including seasonal variation. The company also cautions that its forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.

What's Next

The first DOC review will convene in December 2026, with an update to the market to follow the committee's recommendation. Enrolment will continue towards 40 evaluable patients, and the company is working to open sites in France. CEO James McDonnell will host an online investor briefing on Wednesday, 21 October 2026 at 11am AEDT. After a recommended Phase 2 dose is selected for CTCL, additional studies in peripheral T-cell lymphoma will be considered, and business development discussions on OmniCAR and CellPryme continue.